PBYI / Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance. more_horizontal

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior D more_horizontal

Puma Biotech (PBYI) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to los more_horizontal

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma Biotech (PBYI) and Techne (TECH). But which of these tw more_horizontal

The heavy selling pressure might have exhausted for Puma Biotech (PBYI) as it is technically in oversold territory now. In addition to this technical more_horizontal

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 2, 2023, following the r more_horizontal

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer. more_horizontal

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Confe more_horizontal